Research programme: Bcl-2 inhibitors - AbbVie/Genentech/WEHI
Latest Information Update: 12 Feb 2013
At a glance
- Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
- Developer AbbVie; Genentech; Walter and Eliza Hall Institute of Medical Research
- Class Small molecules
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Feb 2007 Preclinical trials in Cancer in Australia (unspecified route)